High frequency of PTEN mutations in nevi and melanomas from xeroderma pigmentosum patients

Pigment Cell and Melanoma Research

Volumn 27, Issue 3, 2014, Pages 454-464

  Masaki, Taro ^a,b   Wang, Yun ^a,c   Digiovanna, John J ^a   Khan, Sikandar G ^a   Raffeld, Mark ^a   Beltaifa, Senda ^a,f   Hornyak, Thomas J ^a,d   Darling, Thomas N ^e   Lee, Chyi Chia R ^a   Kraemer, Kenneth H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^e Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^f Advanced Pathology Associates   (United States)

Author keywords

DNA repair; Melanoma; MTOR; Nevi; PTEN; UV carcinogenesis; Xeroderma pigmentosum

Indexed keywords

B RAF KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; BRAF PROTEIN, HUMAN; DNA; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; MTOR PROTEIN, HUMAN; NRAS PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; DNA SEQUENCE; DYSPLASTIC NEVUS; ENZYME ACTIVATION; FEMALE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MALE; MELANOCYTE; MELANOMA; MIDDLE AGED; MUTATION; MUTATION RATE; NEVUS; ONCOGENE N RAS; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; XERODERMA PIGMENTOSUM; YOUNG ADULT; COMPLICATION; EPILUMINESCENCE MICROSCOPY; GENETICS; NEVUS, PIGMENTED; NUCLEOTIDE SEQUENCE; ONCOGENE; PATHOLOGY; PHYSIOLOGY; PRECANCEROUS CONDITIONS; RADIATION INDUCED NEOPLASM; SKIN NEOPLASMS; SUNLIGHT; ULTRAVIOLET RADIATION;

ADULT; DERMOSCOPY; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NEOPLASMS, RADIATION-INDUCED; NEVUS, PIGMENTED; ONCOGENES; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; PTEN PHOSPHOHYDROLASE; SKIN NEOPLASMS; SUNLIGHT; TOR SERINE-THREONINE KINASES; ULTRAVIOLET RAYS; XERODERMA PIGMENTOSUM; YOUNG ADULT;

EID: 84898842120     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12226     Document Type: Article

References (48)

1. Ackerman, A.B. (1980). Malignant melanoma: a unifying concept. Hum. Pathol. 11, 591-595.
2. Aguissa-Toure, A.H., and Li, G. (2012). Genetic alterations of PTEN in human melanoma. Cell. Mol. Life Sci. 69, 1475-1491.
3. Alimonti, A., Carracedo, A., Clohessy, J.G. et al. (2010). Subtle variations in Pten dose determine cancer susceptibility. Nat. Genet. 42, 454-458.
4. Baker, S.J. (2007). PTEN enters the nuclear age. Cell 128, 25-28.
5. Berger, A.H., and Pandolfi, P.P. (2011). Haplo-insufficiency: a driving force in cancer. J. Pathol. 223, 137-146.
6. Berger, M.F., Hodis, E., Heffernan, T.P. et al. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506.
7. Bonneau, D., and Longy, M. (2000). Mutations of the human PTEN gene. Hum. Mutat. 16, 109-122.
8. Bradford, P.T., Goldstein, A.M., Tamura, D. et al. (2011). Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J. Med. Genet. 48, 168-176.
9. Carvajal, R.D., Antonescu, C.R., Wolchok, J.D. et al. (2011). KIT as a therapeutic target in metastatic melanoma. JAMA 305, 2327-2334.
10. Clark, W.H. Jr, Elder, D.E., Guerry, D., Epstein, M.N., Greene, M.H., and Van, H.M. (1984). A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol. 15, 1147-1165.
11. Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N.Engl. J. Med. 353, 2135-2147.
12. Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346.
13. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E. Jr, You, M.J., DePinho, R.A., McMahon, M., and Bosenberg, M. (2009). Braf (V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
14. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
15. Daya-Grosjean, L., and Sarasin, A. (2005). The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. Mutat. Res. 571, 43-56.
16. D'Errico, M., Calcagnile, A., Canzona, F. et al. (2000). UV mutation signature in tumor suppressor genes involved in skin carcinogenesis in xeroderma pigmentosum patients. Oncogene 19, 463-467.
17. DiGiovanna, J.J., and Kraemer, K.H. (2012). Shining a light on xeroderma pigmentosum. J. Invest. Dermatol. 132, 785-796.
18. Dumstorf, C.A., Clark, A.B., Lin, Q., Kissling, G.E., Yuan, T., Kucherlapati, R., McGregor, W.G., and Kunkel, T.A. (2006). Participation of mouse DNA polymerase iota in strand-biased mutagenic bypass of UV photoproducts and suppression of skin cancer. Proc. Natl Acad. Sci. USA 103, 18083-18088.
19. Gartner, J.J., Parker, S.C., Prickett, T.D. et al. (2013). Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc. Natl Acad. Sci. USA 110, 13481-13486.
20. Howlader, N., Noone, AM., Krapcho, M., Garshell, J., Neyman, N., Altekruse, SF., Kosary, CL., Yu, M., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Lewis, DR., Chen, HS., Feuer, EJ., Cronin, KA. (eds). (2013). SEER Cancer Statistics Review, 1975-2010. (Bethesda, MD: National Cancer Institute), http://seer.cancer.gov/csr/1975_2010/ (based on November 2012 SEER data submission, posted to the SEER web site, April 2013).
21. Kamiya, H., Iwai, S., and Kasai, H. (1998). The (6-4) photoproduct of thymine-thymine induces targeted substitution mutations in mammalian cells. Nucleic Acids Res. 26, 2611-2617.
22. Karbowniczek, M., Spittle, C.S., Morrison, T., Wu, H., and Henske, E.P. (2008). mTOR is activated in the majority of malignant melanomas. J. Invest. Dermatol. 128, 980-987.
23. Kraemer, K.H., Lee, M.M., Andrews, A.D., and Lambert, W.C. (1994). The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch. Dermatol. 130, 1018-1021.
24. LeClerc, J.E., Borden, A., and Lawrence, C.W. (1991). The thymine-thymine pyrimidine-pyrimidone (6-4) ultraviolet light photoproduct is highly mutagenic and specifically induces 3' thymine-to-cytosine transitions in Escherichia coli. Proc. Natl Acad. Sci. USA 88, 9685-9689.
25. Li, S., Takeuchi, F., Wang, J.A., Fan, Q., Komurasaki, T., Billings, E.M., Pacheco-Rodriguez, G., Moss, J., and Darling, T.N. (2008). Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. Proc. Natl Acad. Sci. USA 105, 3539-3544.
26. Liu, W., Kelly, J.W., Trivett, M. et al. (2007). Distinct clinical and pathological features are associated with the BRAF (T1799A (V600E)) mutation in primary melanoma. J. Invest Dermatol. 127, 900-905.
27. Marsh, D.V., Deuker, M.M., Bosenberg, M.W., Phillips, W., and McMahon, M. (2013). Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J. Clin. Invest. 123, 5104-5118.
28. Miller, A.J., and Mihm, M.C. Jr (2006). Melanoma. N.Engl. J. Med. 355, 51-65.
29. Nikolaou, V.A., Stratigos, A.J., Flaherty, K.T., and Tsao, H. (2012). Melanoma: new insights and new therapies. J. Invest Dermatol. 132, 854-863.
30. Populo, H., Soares, P., Faustino, A., Rocha, A.S., Silva, P., Azevedo, F., and Lopes, J.M. (2011). mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment Cell Melanoma Res. 24, 254-257.
31. Populo, H., Soares, P., and Lopes, J.M. (2012). Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert Opin. Ther. Targets 16, 689-705.
32. Poynter, J.N., Elder, J.T., Fullen, D.R., Nair, R.P., Soengas, M.S., Johnson, T.M., Redman, B., Thomas, N.E., and Gruber, S.B. (2006). BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res. 16, 267-273.
33. Ramensky, V., Bork, P., and Sunyaev, S. (2002). Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 30, 3894-3900.
34. Rodriguez-Escudero, I., Oliver, M.D., Andres-Pons, A., Molina, M., Cid, V.J., and Pulido, R. (2011). A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. Hum. Mol. Genet. 20, 4132-4142.
35. Sanger Institute (2012). Catalogue of Somatic Mutations in Cancer. http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/
36. Stern, J.B., Peck, G.L., Haupt, H.M., Hollingsworth, H.C., and Beckerman, T. (1993). Malignant melanoma in xeroderma pigmentosum: search for a precursor lesion. J. Am. Acad. Dermatol. 28, 591-594.
37. Tsao, H., Zhang, X., Fowlkes, K., and Haluska, F.G. (2000). Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 60, 1800-1804.
38. Tsao, H., Mihm, M.C. Jr, and Sheehan, C. (2003). PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. J. Am. Acad. Dermatol. 49, 865-872.
39. Tsao, H., Goel, V., Wu, H., Yang, G., and Haluska, F.G. (2004). Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest Dermatol. 122, 337-341.
40. Vandewoestyne, M., Van, N.F., Van, H.D., and Deforce, D. (2012). Evaluation of three DNA extraction protocols for forensic STR typing after laser capture microdissection. Forensic Sci. Int. Genet. 6, 258-262.
41. Wang, Y., Woodgate, R., McManus, T.P., Mead, S., McCormick, J.J., and Maher, V.M. (2007). Evidence that in xeroderma pigmentosum variant cells, which lack DNA polymerase eta, DNA polymerase iota causes the very high frequency and unique spectrum of UV-induced mutations. Cancer Res. 67, 3018-3026.
42. Wang, Y., DiGiovanna, J.J., Stern, J.B., Hornyak, T.J., Raffeld, M., Khan, S.G., Oh, K.S., Hollander, M.C., Dennis, P.A., and Kraemer, K.H. (2009). Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. Proc. Natl Acad. Sci. USA 106, 6279-6284.
43. Wei, Q., Lee, J.E., Gershenwald, J.E. et al. (2003). Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J. Natl Cancer Inst. 95, 308-315.
44. Wei, X., Walia, V., Lin, J.C. et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442-446.
45. Whiteman, D.C., Pavan, W.J., and Bastian, B.C. (2011). The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 24, 879-897.
46. Williams, C., Ponten, F., Moberg, C., Soderkvist, P., Uhlen, M., Ponten, J., Sitbon, G., and Lundeberg, J. (1999). A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am. J. Pathol. 155, 1467-1471.
47. Zebary, A., Omholt, K., Vassilaki, I., Hoiom, V., Linden, D., Viberg, L., Kanter-Lewensohn, L., Johansson, C.H., and Hansson, J. (2013). KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. J. Dermatol. Sci. 72, 284-289.
48. Ziegler, A., Leffell, D.J., Kunala, S. et al. (1993). Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc. Natl Acad. Sci. USA 90, 4216-4220.